8 Analysts Reveal Shocking Truth About HealthEquity Stock - Is HQY a Buy or Sell?

Recent ratings from 8 analysts for HealthEquity (NASDAQ:HQY) have shown mixed perspectives in the past three months, indicating uncertainty in the market. The table below highlights the summary of their recent ratings and evolving sentiments over time.

The 12-month price target evaluations have provided more insights into the market expectations. The average price target stands at $102.5, with a high of $105.00 and a low of $92.00. It indicates a decrease in the current average price target from $103.00, a decline of 0.49%. Analyzing recent actions and ratings of key analysts offers valuable insights into the market trend and sentiment.

A closer look at key analysts and their recent evaluations of HealthEquity (NASDAQ:HQY) reveals a mix of perspectives. Alexander Paris of Barrington Research has maintained 'Outperform' ratings consistently with a price target of $105.00. Similarly, Constantine Davides of JMP Securities also maintains a 'Market Outperform' rating with a price target of $105.00. However, Sean Dodge of RBC Capital has a lower price target of $92.00 with an 'Outperform' rating.

On the other hand, George Hill of Deutsche Bank recently raised the rating from 'Hold' to 'Buy' while keeping the price target at $103.00. In contrast, Allen Lutz of B of A Securities has lowered the price target from $105.00 to $100.00 but still maintains a 'Buy' rating.

In conclusion, understanding the recent ratings and price target adjustments is essential in analyzing market trends and making informed investment decisions. Staying updated on analysts' perspectives can provide valuable insights into potential market movements and opportunities for growth.

For more information and full story on this, please visit Benzinga.com